Is FBT a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The case for FBT is simple: low-cost, diversified exposure to NYSE Arca Biotechnology Index at a 0.55% expense ratio, anchored by names like MRNA, GILD, ALKS. If that is the exposure you want and you do not already own most of it through another fund, FBT is a strong core holding. The catch is concentration in its top names and overlap with broad-market funds you may already hold. Whether it is a buy comes down to whether you want NYSE Arca Biotechnology Index and at what cost. Not a recommendation; Walnut is not an investment adviser.
What are you buying with FBT?
FBT tracks the NYSE Arca Biotechnology Index, an equal-dollar-weighted index of roughly 30 leading US biotechnology companies. The expense ratio is 0.55%. Unlike cap-weighted biotech funds such as IBB or XBI, FBT's equal-weight design gives mid-cap biotechs the same influence as large-cap names, spreading exposure more evenly across the group.
Largest holdings (approximate as of mid-2026; verify on First Trust Advisors's fund page):
What's the case for FBT?
FBT is the First Trust NYSE Arca Biotechnology Index Fund, an equal-weighted biotech ETF. It tracks the NYSE Arca Biotechnology Index, holding about 30 leading US biotech companies such as Moderna, Gilead, Amgen, and Alkermes at roughly equal weights. The expense ratio is 0.55%. Because it equal-weights rather than market-cap-weights, mid-cap biotechs carry as much influence as the giants, making it a more balanced alternative to cap-weighted funds like IBB or XBI.
In its favour: it gives you NYSE Arca Biotechnology Index exposure in one ticker at a 0.55% expense ratio, which is simple to hold and cheap to own.
What should you weigh before buying FBT?
- Cost vs alternatives: 0.55% is the fee; compare it to funds tracking a similar index.
- Concentration: check how much of FBT sits in its largest holdings (MRNA, GILD, ALKS).
- Overlap: if you already own a broad-market fund, you may already hold much of this.
- Tracking scope: FBT only gives you NYSE Arca Biotechnology Index; it will not capture what sits outside that index.
How do you decide if FBT is a buy?
The useful question is rarely “will FBT go up?” It is “does this exposure fit my plan, at a cost I am happy with, without doubling up on what I already own?” Walnut connects your real brokerage so you can see exactly how FBT would overlap with your current holdings, analyze it by chatting through Claude or ChatGPT, and place any trade yourself. You stay in control.
The bottom line on FBT
The bottom line: FBT is a low-cost core building block for NYSE Arca Biotechnology Index exposure, not a tactical bet on a single name. If you want NYSE Arca Biotechnology Index exposure and the 0.55% fee is competitive for you, it does its job well. If you already own that exposure through another fund, adding it mostly doubles a fee without adding diversification. Decide from your goal and your existing holdings, not from where the market sat last week. Walnut is not an investment adviser.
Build a portfolio around FBT with Walnut
Use FBT as your core holding, then let Walnut's AI propose thematic satellites: AI infrastructure, dividend growth, clean energy, whatever you believe in. Connect your broker, build the basket in conversation, track it as one unit.
FAQ
Is FBT a good ETF to buy?
+
Walnut is informational, not investment advice. Whether FBT fits depends on your goals, time horizon, and what you already hold. It tracks NYSE Arca Biotechnology Index at a 0.55% expense ratio, so the questions that matter are whether you want that exposure, whether you already own it through another fund, and whether the cost is competitive for what it does.
What does FBT actually hold?
+
FBT tracks NYSE Arca Biotechnology Index. Its largest positions include MRNA, GILD, ALKS, AMGN, HALO and others (approximate, verify on First Trust Advisors's fund page). The holdings are what you are really buying, not the ticker.
What is FBT's expense ratio?
+
0.55% as of mid-2026. Over decades, the expense ratio is one of the few things you can control, so it is worth comparing against close alternatives that track a similar index.
Does FBT pay a dividend?
+
FBT distributes a dividend with an approximate yield of ~0.1% (mid-2026). See the FBT dividend page for how distributions work. Verify the current figure with First Trust Advisors.
What are the risks of buying FBT?
+
Like any index ETF, weigh concentration (how much sits in the top holdings), overlap with funds you already own, and whether NYSE Arca Biotechnology Index matches the exposure you actually want. FBT only gives you NYSE Arca Biotechnology Index, not what sits outside it.
How do I decide if FBT is right for me?
+
Start from your goal, then check four things: what FBT holds, its cost versus alternatives, how much it overlaps with what you already own, and whether the exposure fits your time horizon and risk tolerance. Walnut can analyze the overlap against your real holdings; you keep your broker and approve any trade.
Walnut is informational, not investment advice. Figures are approximations stamped to mid-2026; verify current data with First Trust Advisors or your broker. Nothing here is a recommendation to buy, sell, or hold any security.